Home / Publications / Pivotal trial with plant-cell–expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy

Pivotal trial with plant-cell–expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy

Protalix BioTherapeutics to Present at Two Upcoming Healthcare Conferences CARMIEL, Israel, May 14, 2015 (GLOBE NEWSWIRE) — Protalix BioTherapeutics, Inc. (NYSE:PLX) (TASE:PLX), today announced that Moshe Manor, the Company’s President and Chief Executive Officer, will present a corporate overview at the 2015 UBS Global Healthcare Conference and the Jefferies 2015 Global Healthcare Conference.